Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-24-001904
Filing Date
2024-12-17
Accepted
2024-12-17 15:00:12
Documents
4
Period of Report
2024-12-17

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 10459
2 PRESS RELEASE nymox_ex991.htm EX-99.1 6920
3 nymox_ex991img1.jpg GRAPHIC 4405
4 nymox_ex991img2.jpg GRAPHIC 4460
  Complete submission text file 0001640334-24-001904.txt   30943
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 241555187
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)